<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118895</url>
  </required_header>
  <id_info>
    <org_study_id>17EU01</org_study_id>
    <nct_id>NCT03118895</nct_id>
  </id_info>
  <brief_title>Leaders Free III: BioFreedom™ Clinical Trial</brief_title>
  <official_title>A Study Evaluating the Safety and Efficacy of the BioFreedom™ Biolimus A9™ Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosensors Europe SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biosensors Europe SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study evaluating the safety and efficacy of the BioFreedom™ Biolimus A9™ coated Cobalt
      Chromium coronary stent system in patients at high risk of bleeding
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, open-label single-arm study designed to enroll 370 HBR patients
      (for at least 340 evaluable) at up to 20 centers in up to 2 European countries. 370 patients
      will receive a BioFreedomTM CoCr stent. All patients will be followed up for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>370 high bleeding risk items</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>MACE: composite of cardiac death, myocardial infarction and definite/probable stent thrombosis (safety)</measure>
    <time_frame>at 1 year</time_frame>
    <description>Incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinically driven target lesion revascularization (efficacy)</measure>
    <time_frame>at 1 year</time_frame>
    <description>incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>At 1 and 4 months, and 1 and 2 years</time_frame>
    <description>incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven Target Lesion Revascularization</measure>
    <time_frame>At 1 and 4 months, and 2 years</time_frame>
    <description>Incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven Target Vessel Revascularization</measure>
    <time_frame>At 1 and 4 months, and 2 years</time_frame>
    <description>Incidence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Cardiac Death</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Bleeding</condition>
  <condition>Mortality</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioFreedom™ BA9™ drug-coated stent</intervention_name>
    <description>Drug-coated stent for coronary arteries</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at high bleeding risk (HBR) with an indication for percutaneous coronary
             intervention who can tolerate no more than one month of DAPT. This includes candidates
             with stable angina, silent ischemia, ACS (STEMI and non-STEMI), non-native lesions and
             in-stent restenosis. Patients must provide written informed consent.

        Reasons of unsuitability for &gt; 1 month dual antiplatelet treatment must include one or MORE
        of the following:

          1. Adjunctive oral anticoagulation treatment planned to continue after PCI

          2. Age ≥ 75 years old

          3. Baseline Hgb &lt;11 g/dl (or anemia requiring transfusion during the 4 weeks prior to
             inclusion into the trial)

          4. Any prior intracerebral bleed

          5. Any stroke in the last 12 months

          6. Hospital admission for bleeding during the prior 12 months

          7. Non skin cancer diagnosed or treated ≤ 3 years

          8. Planned daily NSAID (other than aspirin) or steroids for ≥ 30 days after PCI

          9. Planned surgery that would require interruption of DAPT (within next 12 months)

         10. Renal failure defined as: Creatinine clearance &lt;40 ml/min

         11. Thrombocytopenia (PLT &lt;100,000/mm3)

         12. Severe chronic liver disease defined as: patients who have developed any of the
             following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice

         13. Expected non-compliance to prolonged DAPT for other medical reasons

        Exclusion Criteria:

          1. Pregnant and breastfeeding women

          2. Patients expected not to comply with 1 month DAPT

          3. Patients requiring a planned staged PCI procedure more than one week after the index
             procedure

          4. Procedure requires the use of non-study stents, or alternative therapeutic options not
             followed by stent implantation (angioplasty only, atherectomy only).

          5. Active bleeding at the time of inclusion

          6. If patient requires a stent &lt;2.5mm

          7. If patient requires a stent &gt;3.5mm

          8. Cardiogenic shock

          9. Compliance with long-term single anti-platelet therapy unlikely

         10. Known hypersensitivity or contraindication to aspirin, clopidogrel (or to any another
             P2Y12 inhibitor if applicable), cobalt chromium, zinc, Biolimus A9TM or a sensitivity
             to contrast media, which cannot be adequately pre-medicated

         11. PCI during the previous 12 months for a lesion other than the target lesion

         12. Participation in another clinical trial (12 months after index procedure)

         13. Patients with a life expectancy of &lt; 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franz Eberli, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief of Cardiology - Triemli Hospital Zurich - Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Garot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Privé Claude Galien ICPS - France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Schuette</last_name>
    <phone>+44 7970 942 022</phone>
    <email>d.schuette-consultant@biosensors.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dervilla Bermingham</last_name>
    <phone>+41 798275582</phone>
    <email>d.bermingham@biosensors.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>at Hôpital Privé Claude Galien ICPS</name>
      <address>
        <city>Quincy sous Sénart</city>
        <state>Essonne</state>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Garot, MD</last_name>
      <phone>+33.01.69.39.91.69</phone>
      <email>p.garot@angio-icps.com</email>
    </contact>
    <investigator>
      <last_name>Philippe Garot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Triemli Stadtspital</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz Eberli, MD</last_name>
      <email>franz.eberli@triemli.stzh.ch</email>
    </contact>
    <investigator>
      <last_name>Franz Eberli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

